Ihre
gewählte
Nachricht : |
|
| Datum : | 12.05.2014 |
Titel : |
DGAP-News: Proteros biostructures GmbH: Proteros Announces Changes in Management Team |
| Meldung : | DGAP-News: Proteros biostructures GmbH / Key word(s): Change of Personnel Proteros biostructures GmbH: Proteros Announces Changes in Management Team 12.05.2014 / 09:32 --------------------------------------------------------------------- Proteros Announces Changes in Management Team Munich, Germany - 12 May 2014 - Proteros biostructures announced today significant changes in its management team. Michael Grau joined Proteros as Chief Financial Officer, succeeding Arnd Christ whose duties Mr Grau will now assume with immediate effect. In addition, Dr Peter Reinemer, longstanding member of the Proteros management team, was promoted to Chief Operating Officer. Michael Grau, MBA, joined Proteros from Correvio LLC, USA, a healthcare company focused on the commercialisation of hospital specialty products, where he served since 2011 as Group Chief Financial Officer and Chief Compliance Officer. Over the last 15 years Michael Grau held senior management positions in several leading international Biotech and Medtech companies in Germany and Switzerland. Previously, he held management positions within Warner Bros and Paramount Pictures and prior to this he spent several years with KPMG. Michael holds a BA in European Finance & Accounting from the Leeds and Bremen University and an Executive MBA from the Henley Management School, London. Dr Peter Reinemer, MBA, who has served as Senior Vice President Business Development & Operations at Proteros, has been promoted to Chief Operating Officer. Prior to joining Proteros, Dr Reinemer held positions as Section Head Enabling Technologies at Bayer, Germany, Director Screening Technologies, Bayer Yakuhin, Japan and Managing Director of a Joint venture with Khazanah Nasional/Biotropics, Malaysia. Dr Reinemer holds a Ph.D. in Biochemistry from the Max-Planck-Institute for Biochemistry, Germany and an MBA from the Austrian business school Schloss Seeburg. He is also co-founder of IMD Natural Solutions, Germany. "We are very glad to have Michael Grau joining our company as the new CFO, enriching the team with his many years of executive leadership experience and industry know-how", commented Dr Torsten Neuefeind, Chief Executive Officer of Proteros. "Together with our COO Peter Reinemer, we have now accomplished a strong management team to lead Proteros through its next stage of corporate growth and to further strengthen our position as leader in structure accelerated drug discovery. I also would like to thank Arnd Christ for his contributions to Proteros and wish him all the best for his professional future." On behalf of the Company's supervisory board, Dave Lemus, Chairman of the Board of Proteros commented: "We are very pleased to appoint both Peter Reinemer and Michael Grau to the senior management of Proteros, particularly as the Company transitions into its next phase of growth. Moreover, we would like to thank Arnd Christ for his service to Proteros and wish him success in all his future endeavours." About Proteros biostructures GmbH Proteros biostructures, located in Martinsried/Munich, is a privately-held company, focussing on protein-structure accelerated lead discovery. Proteros has established a unique and powerful platform for the integration of protein crystallography, biophysics - particularly kinetic and thermodynamic profiling-, tailor-made protein production for biophysical applications and Medicinal Chemistry. Proteros collaborates with more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. For more information, visit: www.proteros.de Contacts: Dr Torsten Neuefeind, CEO Proteros biostructures GmbH Email: neuefeind@proteros.de For Press enquiries: MC Services AG, Katja Arnold Email: katja.arnold@mc-services.eu Phone: +49 89 210 228-0 End of Corporate News --------------------------------------------------------------------- 12.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------- 267639 12.05.2014 |
| Sender : | |